Study of FPG500 in non-spread prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new approach called FPG500 in men with prostate cancer that has not spread beyond the prostate. It aims to see if it helps with treatment or monitoring, and may be an option for those considering surgery or active surveillance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer that has not spread to other parts of the body (non-metastatic).
- Your cancer is classified as low-risk, high-risk, or locally advanced by your doctor.
- If you have high-risk or locally advanced cancer, you are planning to have surgery to remove the prostate.
- If you have low-risk cancer, you are either planning to have surgery or are choosing active surveillance (regular monitoring without immediate treatment).
- You have not had other cancers in the past or currently.
- You are not currently taking hormone therapy or other medications specifically for prostate cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether targeting only the visible cancer spots on MRI (focal therapy) works as well as treating the whole prostate, for men with small, moderate-risk prostate cancer that hasn't spread.
This trial tests a new type of imaging scan called FAPI PET/CT to see how well it finds the spread of prostate cancer compared to the usual PSMA PET/CT scan. If you join, you'll get an extra scan that might help doctors understand your cancer better and guide treatment decisions.
This study is tracking men who choose focal therapy (a targeted treatment) for their localized prostate cancer. It aims to learn how well this treatment works and how it affects quality of life.
This study tracks men with intermediate-risk prostate cancer who had a newer, targeted treatment that only treats the cancer area, not the whole prostate. It aims to see how well these treatments work in real life and may help guide future care.
This study tests a targeted treatment for prostate cancer that aims to treat only the cancer while sparing healthy tissue. It may be an option for men with low to medium risk prostate cancer.
This study uses a PET/CT scan to learn how and why prostate cancer becomes resistant to treatment. It may help researchers better match future therapy choices for people whose prostate cancer is progressing.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.